Pipeline
Our Pipeline
Pursuing first-in-class therapies targeting the PAM (PI3K/AKT/mTOR) pathway
The PAM (PI3K/AKT/mTOR) pathway has been implicated in breast, prostate, endometrial, ovarian and hematological cancers, among others. We are currently developing REVTORPYK, an inhibitor of class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2, to treat advanced breast cancer and metastatic castration resistant prostate cancer.
REVTORPYK (Gedatolisib) Clinical Pipeline
HR+/HER2- Breast Cancer – Advanced or Metastatic
- Phase 1 PH 1
- Phase 2 PH 2
- Phase 3 PH 3
- Approved Approved
Prostate Cancer – Metastatic Castration-Resistant
- Phase 1 PH 1
- Phase 2 PH 2
- Phase 3 PH 3
- Approved Approved
HR+/HER2- Breast Cancer – Advanced or Metastatic
- PH 1
- PH 2
- PH 3
- Approved
- PH 1
- PH 2
- PH 3
- Approved
- PH 1
- PH 2
- PH 3
- Approved
- PH 1
- PH 2
- PH 3
- Approved
- PH 1
- PH 2
- PH 3
- Approved
- PH 1
- PH 2
- PH 3
- Approved
Prostate Cancer – Metastatic Castration-Resistant
- PH 1
- PH 2
- PH 3
- Approved
The safety and efficacy of REVTORPYK has only been established in combination with fulvestrant, with or without palbociclib, for the treatment of adult patients with HR+/HER2- locally advanced or metastatic breast cancer without a detected PIK3CA mutation following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
2L, second line; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; PIK3CA, phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha; 1L, first line; mCRPC, metastatic castration-resistant prostate cancer
